System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Mark Stoové, PhD is an expert in Infectiology at Burnet Institute (Australia). As of October 2026, ScienceLeadR ranks Mark Stoové in the top 1% of experts worldwide for Hepatitis and Sexually Transmitted Diseases. Mark Stoové has authored 411 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 4 of them ongoing. SLR score: 1,282 (community average: 125). How the SLR is computed.

LeadR Profile

Mark Stoové, PhD Burnet Institute Australia
1 282 ScienceLeadR Reputation 1282

Unlock

Register Login
Network Map

Infectiology

Subspecialties: Public Health - Hepatology - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2007 - 2026
Source: PubMed

Burnet Institute

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 411

Citations

Citations: 7 110 1st author: 12 Last author: 99 Unique author: 2

Main journals

Int J Drug Policy 30
Sex Health 25
Med J Aust 18
J Hepatol 17
BMJ Open 13

Best Journals

JAMA 1
Lancet Gastroenterol Hepatol 1
Lancet Infect Dis 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Chlamydia and gonorrhoea testing and positivity among women prescribed opioid agonist therapy in Australia.
PMID 42949311 — research design, sexually transmitted diseases, epidemiology, pharmaceutical preparations, drug therapy, aged, sex, therapeutics, history, chlamydia		Sex Health20260
Ten-year longitudinal study of incarceration among a community-based cohort of people who inject drugs.
PMID 42900302 — longitudinal studies, pharmaceutical preparations, history, demography		Health Justice20260
Stigma reduction as quality health care: A qualitative study of structural level mechanisms to address stigma.
PMID 42709689		PLoS One20260
Rapid cross-sectional impact assessment of an earthquake on the continuity of antenatal care for pregnant women living with hepatitis B in Vanuatu.
PMID 42542601 — disasters, pregnant women, tenofovir, prenatal care, fumarates, earthquakes, peripartum period, hepatitis b, antiviral agents, hepatitis, health services, natural disasters		Dialogues Health20260
Monitoring of the Cascade of Care in Patients With Chronic HBV in Primary Care Clinics in Australia.
PMID 42402793 — records, therapeutics, hepatitis, viral, human, hepatitis		J Viral Hepat20260

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 6
Early Phase 1 1
Phase 4 1

By status:

Recruiting 3
Completed 2
Active not recruiting 1
Not yet recruiting 1
Unknown 1

By type:

Interventional 5
Observational 3

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 1
multicentric5to9 3
multicentricup10 0

Main Topics

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Low Dead space Injecting Equipment Distribution Program for People Who Inject Drugs in Low and Middle income Countries
NCT06395129 — hepatitis c, needle-exchange programs, blood, focus groups, pharmaceutical preparations, syringes, income, acquired immunodeficiency syndrome, viruses, needles, hepatitis, harm reduction		N/ARecruiting2024
Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia Georgia and Tanzania
NCT06159504 — research design, hepatitis c, point-of-care systems, pharmaceutical preparations, tablets, sofosbuvir, nucleic acids, viruses, therapeutics, hepatitis		Early Phase 1Recruiting2024
The SIMPLY B Study
NCT05614466 — pilots, feasibility studies, carcinoma, hepatocellular, hepatitis b virus, algorithms, herpesvirus 1, cercopithecine, viruses, therapeutics, hepatitis b, hepatitis, health services		N/ANot yet recruiting2023
Same visit Hepatitis C Testing and Treatment (The QuickStart Study)
NCT05016609 — research design, hepatitis c, blood, capillaries, point-of-care systems, antibodies, pharmaceutical preparations, polymerase chain reaction, drug combinations, hepatitis c antibodies, viral load, reverse transcription, sofosbuvir, viruses, hepatitis a, therapeutics, edetic acid, point-of-care testing, hepatitis, reverse transcriptase polymerase chain reaction, rna		Phase 4Recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS